0001387131-12-002109.txt : 20120710 0001387131-12-002109.hdr.sgml : 20120710 20120710172220 ACCESSION NUMBER: 0001387131-12-002109 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20120710 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20120710 DATE AS OF CHANGE: 20120710 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TherapeuticsMD, Inc. CENTRAL INDEX KEY: 0000025743 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870233535 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-16731 FILM NUMBER: 12956542 BUSINESS ADDRESS: STREET 1: 951 BROKEN SOUND PARKWAY NW STREET 2: SUITE 320 CITY: BOCA RATON STATE: FL ZIP: 33487 BUSINESS PHONE: 516-961-1911 MAIL ADDRESS: STREET 1: 951 BROKEN SOUND PARKWAY NW STREET 2: SUITE 320 CITY: BOCA RATON STATE: FL ZIP: 33487 FORMER COMPANY: FORMER CONFORMED NAME: AMHN, Inc. DATE OF NAME CHANGE: 20090930 FORMER COMPANY: FORMER CONFORMED NAME: CROFF ENTERPRISES INC DATE OF NAME CHANGE: 19970915 FORMER COMPANY: FORMER CONFORMED NAME: CROFF OIL CO DATE OF NAME CHANGE: 19920703 8-K 1 thmd-8k_071012.htm CURRENT REPORT

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 10, 2012

 

 

THERAPEUTICSMD, INC.

(Exact name of registrant as specified in its charter)

 

 

Nevada 000-16731 87-0233535

(State or other jurisdiction of incorporation)

 

 (Commission File Number) (IRS Employer Identification No.)

 

951 Broken Sound Parkway NW, Suite 320, Boca Raton, FL 33487

(Address of principal executive offices and Zip Code)

 

(561) 961-1911

(Registrant’s telephone number, including area code)

 

N/A

(Former Name and Address of Registrant)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

£Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

£Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

£Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

 
 

TABLE OF CONTENTS  

 

 

Page

Section 7 – Regulation FD

 

Item 7.01 Regulation FD Disclosure 

   3

 

Section 9 – Financial Statements and Exhibits

 

Item 9.01 (d) Exhibits

   3

  

 
 

Section 7 – Regulation FD

 

ITEM 7.01 REGULATION FD DISCLOSURE

 

On July 10, 2012, TherapeuticsMD™, Inc., parent company of vitaMedMD®, LLC ("vitaMedMD") ("TherapeuticsMD" or the "Company"), plans to file up to three Investigational New Drug applications ("INDs") with the U.S. Food and Drug Administration this year and if accepted, will initiate Phase III clinical trials in the field of hormone therapy for menopausal women. During the same time period, the Company expects to file additional patents for these products.

 

The information in this Item 7.01 of this Form 8-K (the "Report") is being furnished and shall be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Act"), or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Report also shall not be deemed to be incorporated by reference into any filing under the Act except to the extent that we specifically incorporate it by reference.

 

Section 9 – Financial Statements and Exhibits

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

 

(d) Exhibits:

 

Exh. No. Date Document
     
99.0 July 10, 2012 Press Release regarding INDs*
     

____________________________

* Filed herewith.

 

 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 10, 2012   THERAPEUTICSMD, INC.
     
    By: /s/Robert G. Finizio
    Robert G. Finizio, Chief Executive Officer

 

 

 

 GRAPHIC 2 logo.jpg begin 644 logo.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`! M````/@```!L!!0`!````1@```"@!`P`!`````@`!`3$!`@`0````3@`````` M``!@`````0```&`````!````4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`"\! M5@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_ MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($ M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B M7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X MN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$` M`A$#$0`_`/[V]9UG3]`TG4=H7)4O\`9[&PMY;NZG*)EW$5 MO#)(516=@N$5CQ7Y/R?\%V/^"5:.R/\`M8>&%=&*.K>$_B""KJ2&!SX2.2". MH)!Z@D.:%G M@GD598G22-B'C=752/Q6N?\`@W6_X),S2R7$G[/7B9Y9I6DD)^./QN.YY&+N M3_Q7XP"2>%X&<``#CU\JCD#]K_;*C[*.$@V^K;G425[IZ#_P_:_X)4_] M'9>%_P#PE/B!_P#,C6WX:_X+-O&MG?6<7ASP?I.K:0K^+ M;/7H/%MU]FO[N>9C=:U,9PPBG,D2J@_J)\)_\&_O_!+'P)XK\,>-O#/P!\16 M/B+PAX@T?Q1H-Z_QI^,]Y'::SH.HV^J:7*2)W5OJLYR;@W*'AZ53$<1U*^,RZEC\,DL+*ER8B*=&%=NO&2=U^]45)* M+?+*3/BLCS[CW/%B:M&APO"A@LRJ9;B>>69JK*="HH5IT(N=2G*+C=T_:N-W M92@E<]*^.?\`P5B^`GP"_;=^%?[!_BWP5\4]5^*7Q<'@'^P?$6@Z5X5F\"V# M?$76=3T31O[6O;SQ;IVO0&UNM*GEU$6^A792UEMY8!=2.T,?ZN+T'T'KZ>_/ MY\U_$S_P4^GL]+_X.-OV+[V[FM[/3].MOV8+V]O;J9+>UL[.W\?>-9Y+BXGE M9(888(T>2665E2.&-F9@B*/B%?:5?2:;K M6M?#3P%K/B'PIIEU`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`&M_`"?$W]GSXH>& MOB;X.:<6D^HZ)-/#>Z7?>3%.^F>(-$U.UT[6O#^JQPS0S2:;K&G6=VL4\4OE MF*6-F[,5E&:X*DJV,R[%X:D[+VE:C*$$Y)-)SE:*;3NDW?R//P/$.29G6^KX M#,\)BJ[4I*E2JJ4I1C+EE*/1I2TT=_*VI]'45\"?M!?\%(_V4_V8_CO\+OV; M_C%\1M1\,_%SXRR>&E^'WAJR\">-O$L&L_\`"7>)W\&:#YNN^'_#FI:)I:W. MOHT4S:IJ%JMM%^_FDCME:0>+_M1?\%H/V!OV1O'$OPM^*7QH.H_$NVNH;'5/ M!?P]\+:YX]U3P]([_`$*RD\.Z)?1,X,VD:GK-IK,0(9M+`$@BSH9; MF6)=)8?+\9656BZ\)4Z$Y1=*-^::=M8PM[S5TKJS=]-,1GF481U8XK,<)AY4 M:WL*D:M>FI*J^7EA92;O/F]U-*]G>UC]8Z*^)_VHO^"A'[(O[&-M:3?M'_'/ MPC\/+W4K!=4TOPU<+J6O>,]2TUI[BU2_T_P7X3T[7O%MY92W5G=VL=Y%HAM6 MNK2Z@$P-M.T/YVZ!_P`'(7_!+C7/$$6@S_%OQOX>MYY$AA\3:_\`"+Q_#X>, MCOM4S-IFBZMJ]I;,V$:\O-)M[2T!\V]GAC!<;8?)' MG*+:=I*+2]YP^TE=HQQ/$N08.NL-BLWP-"L[>Y4KQ32DDXMVO9237+W['[U4 M5Y7\,?BYX!^,W@O0?B/\+/&WA[Q[X#\4V4>H>'?%'A;4+75]*U2UD1LF&XMO M,"SQ2*\4]O-Y4]O<126US%%<*\*?&?P]_P""JW[$WQ+^(_QO^%V@_&FUT_Q1 M^SCH_B77OC+)XM\->)O!/AKP;I/@_P`46_@W7[N7Q3XJT73-!U-;7Q)=VVG1 MMI.IWJ7AD\ZR%Q%@MR4\+B:WMU2P]>%8?BI\0->TV.[-G-XXT+X1^,KCPE"ZM$KSJ][8:=XCOK)#( MY%SI?AN_CN%MY);0SQ-`T_ZX_L__`+3'P4_:B\!V'Q/^`OQ+\.?$_P`":@[6 MZZYX=G8BQODBBGDTS6=.O(;35M$U>&*>!Y](U:QL-2MHYHI)[18Y8Y'Z,7E. M:X"E"OC/?"'P^\*Z]XV\;>*]"\)>$_# M6F7.K:[XDU_4;/3-'T?3K:)I9;Z_O[V6&UM[:-5RTDLBJ20@)9@#^(WB_P#X M.0?^"8'A3Q;-X7M_BEX]\6V5I/);WWC+PI\*/%-WX3MV@53--%<:E;Z5K&IV MJ9:1+S1=$U2VNHT\RPDNXF1VG"99F&/YG@\'B,3"-E*I1IRG",G;E@Y137/) M7:CN[.W0>89YE&5.G',LPPV"G5DH4Z=>K&$YR=DK1N]'?=Z=^A^]U%?,'[-? M[7G[/W[7?@1?B/\`L[_%;PW\3O"OVC['=7.C_:+35-%O3&DR6'B+P]JT%AKV M@Z@86\Y;/6-.TZ>6(&YMXIK8%AY5\1_^"C7[+'PG_:F\`?L:>./B)J6E?M`? M$Q?#C^#_``A%X$\9ZA8ZDGBVXU"ST`S>*=/T"Z\,V'VVZTN\C9;S5('MRBM. M%1UK%83%RQ&(PL<-7>*PL'4Q&']FU6I4E\524'9J"U3?22:=F=$LSR^%&CB9 M8R@L/B*D:-"O[1.E5K3:2I0DKWFKW:LM-4V?>E%4WDF$)*D>9A1\HSM+$`D? M(=VP$L!L^;&"!G(^#=4_X*2_LIZ)^V!;?L'ZK\1-1@_:;OY]-MK3P,/`?C=] M/DDU?P;'X^T__BL(O#\G@]1/X6E74"C:X)(WVVTIBG;RQ%&A7Q"FZ-&=5TH> MTJ*"YG"G%KGG*VT873D_-6NVC7$XS"X-1>)KTZ,:E6G0IRJ2Y8U*M7^'3@]; MRELE;H^Q]7_$/XM_"GX2V.GZG\4?B+X(^'.G:M>MINE:AXY\6Z!X4L=1OXX3 MGZMI-Y:ZCI>J6=O MJ&FZC8W,-Y97]A>1+<6=[9W=L\MO-H/#GA[PI)I<>J3>#/[,^SKKRM:)J#7K: M<8P+E;Q[0B8_25>$,SI9%EV;TZ&.Q%7%O%3Q%".'GR4,'"&BKO6C4<>=Z+W=$ MV?I3^W)_P44_9G_X)[:+\/?$/[26M^*=%TWXEZIK^C>%7\,>$]2\527%]X>L M]/OM22[ATW,EHBP:C:B!Y%(N)9/)CS)A3])=)M-9TN6XM)"9+6>2QO('EMW)>&0M&WS*:_)O M_@KM>?\`!,>V\"_!C5?^"G%I>W_A"/Q9XFM/A4VGVGQ:NY8?$=YI&F7>OK)% M\)(9;](VTZPLSOUA?LS)!BSWW;^1/^G7PA'@33/@W\+H?A8!:_#:S^'G@Z+X M?Q2M?*;?P-#X?TQ/#2RKK3_VH@BT,62RG4R=10`FZ!NMX/CXFAAHY5E^)IX7 M,(8FI6Q#K5ZB<<)64*DJ*AAXJ\ZDJ48_O8N*5XOEOU]K"XO%5<]S/!U<7EU3 M"T*.'=#"T[RQN';A"K*>*W_ M`()N_LY>*M3\#:]\:K[XA^+=$N19:SI'PB\'ZSXZ@TNY$ACDAN_%%O#I_@J: M[BD!CFT_3_$=UJ%NTW_`+('_!6S]AO]MK7/^$0^"7QJL;CX@+') M,?AUXUT/6?`7C*XBC\]F.D:?XDLK*R\2F**WFFNE\*ZGKIL(HW^WFVECE1:G MDF;X">)4W M2=-8B%_:II.DG>SJ)NUKVOU/TRHKP_XX?M`_"C]G#X>:[\5OC9\0/#_PX^'_ M`(=\L:IXD\17"PVL%9K[4M2NY/DLM-TRVO]1O')6"REVL5_(C2 M?^#C[_@EO?\`B8Z#>?&#QQH^G"9X$\7:G\'?B)%X8E(D""8"VT&[\200;B?W MU]X=LU5%,TR1P%9VRP>5YGF%*=?`Y?B\51IM)U:-)RB]N:VSO"]I)I-.RZHU MQV>Y1E=6%',S5WT=OWCE<1QNY&0JDX MXY]AD@9^IQ7RSX;_`&P?V<_%7QFUG]GW0OB7I-W\6M"O-8L-0\'26NJ6E['? M:"L6,&GWMU8PR?:9K:SNYYA:QS70C,,4LB^@_!WX]?"']HGP38?$ M3X)?$GPG\3O!&HR>7;^(?!^K6FK6)F4KYEE=F%C<:=?P[D:XT^^AM;V+34LPJX^EC)U,)B, M-0BZ%*JO9N6)G/DA3:G'XKM-[*UK/FT/QGQL\6,R\-L)P?F&2992SVAGF>3P M>/I4E*O6GE6'PT<7C,1@(TDXU*N'HJI5E&I.FN6$G?1G]O*$%%(P054C!!&" M`1@C@CT(X-03.J$LW``YX&&`!.&.00!V]_J*^0?V+OVK_#7[6_P.\,_%+0Y[ M:RU-HFT7QGX?$BM-X;\7:9#"-4T^8RXD-M,7CU'3)VS]ITF^L;DDM)*L7!_\ M%"_VQ=+_`&0/@5K/BR.:TOOB#XM@G\,_##P](T;->^)KJ!P^KW,*YDDTCPW; MNNJ:C@Q+*8K;3DD:ZU*V5/)CE^*EF*RQX>H\6J[HRIJ,6Z4H^][25Y*T'%-Q MFKWOZV_2L3QUPYA^#9<K4K2C1C2 M;C/VK46EJ>N1?MA_LYW'QP3]G"T^)&DW?QBFN+JV'@ZV@O;F=;JQT2X\1WEK M)?P6SZ5%=6FC6EU>W5N]\)K9()(ITCGVQF+XZ?MC?LZ_LVZGH>C?&KXB6?@B M^\1V%WJ&C076F:Q?B]M+"YM[2ZEC;2]/OXXS#/<1AEG:-BI:1=R*6'\NW["7 MP]^)?@#_`(*?6?^*X^%/Q5U"WDUV25I&D MUNZ6-[_4-[F:TN;ZYT]X[>2&X6;[F_X+#^'M&\2_MD_L*>&==T^#5-#\0:C; M:+K.G709H=0TS5?B+X:LM0LYV5EE\JZM'DMY=DB'RY90I&]L_4RX=P<,WP6! MGBJTL/6RZIC*\Z:BZBJ4X-RIQNU%.,H.*?,UL[L_G'!>/O&.:>%_$_&N'R#+ M,NSG*^.LMX4R[+TXOC<4:[TNZNH%D4 M`[XBXDC;*NJ,"*^.[O\`X);_`+!NIZ9-8R?LX^#;;[6DBOQ&<,KR MV][;:JLUK*H.4DA9'!``(48'Y)_M.?L6_%7_`()KZO+^UA^Q;XQ\3P_#OP]? MVW_"Q/ASK<]WJMI8:%/?+:1R:GB6$>*/")GE2*87\$NM>'FN3J<.J2AI[V'@ MIX+),;-8?`8C'4,6YJG16-E!T*E25E9RC*3B[;>Z]>A]OC.,O&7@;#PXAXPX M>X2XAX7H4XXG.L3PA+,X9SDV"E3=6IC%@\;",<9@\-&+E55&I[6"3DX..W]! M'Q-^.OP]^$5_X>M/&\OB6*?Q/=&ST-=!\#>,_%RW%_\`,$L0WA30M92/4IE2 M>6UTZ0I>WEO:7MS:P36]C=RPY#_M.?`V."[N9OB!HT"V7Q3TWX+30SM-%>I\ M4-8U"STO3O!HL'C%Z^JWES>VTL2Q6[VYL&;4FG%A&UR/'?@Q\0_#'[<7P3^! M/QK\.7IT&'3/%VD>,M6T40KJ%QIWB'PWIVM:+K?A&YG9K4JD=[JCR0WRQ.9[ M,6]R+5$N#Y>3?_L'?#R_UJ'QE/=W`\-G]]V[)-&LL7".-PSC/)/<%@>0>02IZ@D' M-%1VB>3;Q1KPJKA?O'Y`<@$`\#!Z`#`!7GI*%XJS2;M=:VO=)ZO;;?N MC]#@JG)"ZC"7)!SBMHS<8N:V_FOOKT?4OTQ^@^O]#3ZAE/0`]""WT_SZ?C4M MV3;LDNK=EVU?370T?1=Y12];H_BN_9._Y6C/VB_^PO\`&G_U7V@5_:>W(`]5 M/\S7\5_[)K`_\'1?[1I'1=8^-08^F/A[H!.?\]:_M0++A>>Q_0DU]KQS>.+R M&^G_`!C65[Z?9U_`_-_#Q_[%Q"E\4>*LQNNJ?M=+KH_)_J?P2_\`!>GX2ZO\ M>O\`@M3\%?@AH&HIH^J_%GX;?L^_#Z#5Y6*QZ9'XM\:^-]'N]2<(6DECT^QN M+N:2W$)%SE+4F1+B6)OZ:O`/_!$'_@FKX!^%-C\+KC]F'X=^-Q'I,=AK7CSQ MGI?]J_$?7+V2U%O?:R/&9F@UKP]?7K>;((O"MUHEI9O(JZ?;6T:^6?P:_P"" MFY!_X.0OV)`<$!/V6#@X(S_PL7QEC(/!.5!&>00",&O[4BI*#@]5]ONDD>G0 MC/Z&NO/,SS+!9)P?0PN+Q&#A+*(5D\/4E0G.3Q<[.4Z?+.<%RNT7)Q\MV]H?PK?L M3?#;6_\`@FA_P<'7'[)7P[\0ZW>?"KXFS:SX7AL]4NY'_M?P#XH^'5S\4_"B M:Y#''#!>ZIX-UO28],@U5X_/N#97%Q#]DBU74;2X]4_X+U_&CQ7^U+^W]^S_ M`/\`!,[3_B+IGPS^$FD7_@'5/BSK^KZM#I/AR/Q%X[,>KGQ%XIGOIX+26'P% MX`2/5/#EA?3QPRZKKUP?/CN+C3KBSZ3X[*!_P=3?`A!\J"V\'$#G`(_9Y\9* MI]3P!GGG`[XKY%_X+E?`7X?^%O\`@LEX(\?_`+2@\4:1^S3^TU9_">Y\4>,? M#=V=.U#2=)\,^&]`^$_BZYTS4[C3]3A^T>#CH6A:_K5G;V=_=QZ3JBI)ITES MJ%C*?K<(J6*X@R;&8Q6QM;@QXV-6G1A6KUL;[*45B%2G.G&IB/8N56,'*+DX M*@G:] MFT?T*_#7]B/_`((<_#?X2Z9\*3I7['/C*SAT2#3=8\8^._&'PW\2?$;Q)=+9 MQPR:]?\`C>ZU;^WK36+F5#>P2Z'=:79Z=/*W]B6&E(8EC_`;X%ZGX2_X)3_\ M%LO!'PL_9Q^*EAX__90_:9U3P9X5N++2/&6F^--%L_#GQ.UNX\/:)9:K?Z5? MW.G2:]\,?'5OY]AJMXD>OQ^$FG6X+6VO337'ZQ^&_P#@V8_X)G^+]`T?Q5X6 M^(OQR\0^'->TVSU;1-%-2TG5=*OX(Y[&^TR^L_!;VUY97-L\&H6_B&;0?-U"VM(M,47R>/A< MTR&C#-L/4S?B//:.*R[$T\1@<=@$J2KU:;5/$.%6KB'0>'K77M8.G:,>5^ZK M'O8G*<\JRR:O1R7AG(EA,QPTL/B\'CW2]O3]I&+H1<)QCB_:03DX7JN^O<_, MW_@YRU;Q-X;_`."AG[,GB+P1>7=AXRT#X+>#]:\)7^GC=J%EXFTSXJ>*+[0+ MRP!5E:]MM4@L[BW5@RF:-U3P_JFB:WK>KZ;J%U*NN:]K>K MWB:MJ4=R]I8Z?92F!_@__@N[96>I?\%E_P#@G'87T$=Y8WI_9\M;NTE19H+F MVG_:+NXI8)XI`R2P31DI+&X97C=E8$$@_P!JR*$CVCC"X'_?`],?G].:Y\]S MO,,NX5X/P&!Q%6@J^5U<15JTI^SG/#5:\J5*G&I&TN6%IN2BUS72?1/LX?X> MP&9\7<:XW,<-0Q,L'F=&-.C-*="%54(3DW!OEYTXIWDN:)^+7_!27]FG_@E= MXX\;?#;]HG_@HIXC\,>&F^'OAW5/!/ABQ\4^.;KPQIOC+3)-8?6QIEUX?\.R M1^,?&4OA^ZFU![+3-+G:*`:QJ4LMC<&X+1_F#\0]:_X-?_C1X/U+X8:3J?P: M^%VHZE8S:3X=\?\`@SP'\4/A_K^A:M-#+;V&KQ>*?^$6MK*\FM'5)43Q8UYI M,Z1^1?6\@VQ'X4M/A;X9_P""H7_!?#]H'X1?MB>,M;M?AY\,_$7Q4\/>"_A^ M^NWNBIK>B_"'7+30/"WPWTFXM[FSNM+@UBQDU/QSK<^DS17^H16NM7-AJ-O+ MJ$]U7])WC?\`X(]?\$DM#^'>M77C/]E3X.^&/"/AS0;Z^USQ+=:CXE\-WFFZ M-86\UU>WNJ>,+3Q+I^LK%:6\+S7%S<:F^P1"$IPK_O*:BFU*M4O_`!+IW=DELB*T)RQ=XJ-KNR=S\1_^#83XI>)/"GQU_;._9"M/&D7 MCGX6>&[2X^(/@K6-,OUOO#L^H>&/'3^`-4\5^&Y8I)8)K#QYI^JZ!JKW%NYM M[M-(L+R$LLTQ;\O?V>OV(]8_X*`?\%?/VIOV?Y?%>N^$?A8/C'\;?'/QQO?# ME^]E?:A\._"7Q8E,6CVBR1RVDNI:GXIUGP_;:?)JMAJ=II=S/H_AC:W<]W=75K\/H_CSX<3P;;75 MS?SSW]Q/;^&_[,BFGOY9;ZXO+_P#@F7^UQ\.OV5O^"W?[7%E\ M6-:L/#/@GXZ?$;XY_">+Q+JUS!8:-H'B^?XPOXB\*76K7TQ2.TL+Z;2+_0%O MKB2*UMK[6E-S(BJIKZ[$U,53SKC;$9;2Q,\;+(LLKVKTH?675=&C>K.C&-YU M&KS3E%WE:7Q:OXVC]6Q>2<$4--:UO M]FS]HS5O!VCPV&K3,R:WX)^)U]J'AGP->:K;P&WTUO&/PX\=QOI[:I9VL*W> ME#4(X+'2[3Q-]DL?[IX-5TUK0WJW]JUEY(N_M8N(VM1;-$LJS"X&(C`T169) MBVV2)A*K%"&K^'?]L_Q_H?\`P44_X+_?LP_#SX"WD/BWPY\"?%GPQT'6?%^A MM'JNBW4WP>\9:A\6?B9K=OJ4$CVAT;P_'#-X?2YBG\JZUNS,2/^W&48WNW M=W/6_P#@X,^.GC']H;]L[]G3_@F=X9\>Z;\.OAS?3^`O$GQ6\1:WJJZ3X;'B MGQUJUZ-,O?%]U)<6MO+H7P]\&VJ^+X!J-T+:XO\`7IY]B:CIFER2_K'\)/V' M/^"('PG^$MG\)EM_V.O'EN-'73-<\:_$;Q=\,/%7Q#\278C<-K5[XOO=174M M/U(73O?V8T,Z99Z-=,6T.TTY(X%@_`3_`(+\_`CP7X0_X*R?!WXG?'^V\5P? MLS?'WP[\,6\8^)?"LKV.J:78>%+J;P5X_M-(O[FUU")=:\-Z/9^&_%3VLELT M,MIJ=G%%#([7#VGZS^%O^#:+_@F/XX\/Z+XL\)_$;XZ>(_"WB'3;75-`\0:+ M\4/!^HZ+K&GW<:RP7^G:E:^#)H;RWN5D4Q2QR^6P4^6N,,>_&5,JP_#G#47F MN:95AZN%^LU)Y92@H8G,)5?WGUBNY1;JTTHJ-%R7+&3M%7:?@82EG..XGXHG M#),HSG%4<8J%.GG>-=&>&P<8?N9X3#SP]=2IR7,Y8A0B^9*TWT_)OP)J'@7_ M`(),?\%K?ACX;_9>^*>F^/OV4_VE-8\(^'=5T70/&FG>+](M/#WQ-U[4/"=O MX5U;4M*OKB&ZU#X9^.KRVUSPK=:B\FK)HK117EW=?:]6DU#Z@_X*!2*?^#EO M]AXKG:]K^SJP(.>OB?QRN#UY^4GC@J5.$;G6[MO!.M:;K-O%?6(\)0Q;KZ:P6 MZCT*ZD@U>]TFUU;4=-@-EID]\GQW_P`%:_&VD?`'_@X!_8Q^,WQ'DDT3X>:5 MH7[//B"_\0W2-#I]KX33>81P=+"2XRR^KA\+A,9'&4L')RI*M%5;N4*;NXQC+E6J]R+>G M]MJ@LNX''*,0>>#@XS],#/>OXJ_BF0W_``=@>$^,G^W/AUUYX_X9`T]/IRS; MB?;FO[.8O$&B7.BP:Y8ZQIMUHMQ8P:G;ZO;7UM-ID^G2PIV\1>#&^)Z^#M-\0: M?+[P+JNIZ/?6Q-O?:3/K/AZ]-A>V\LUO=0*DT$\L+(U?*\% M4*DI\2U8+W,/PWF<*[=G&$YJD_9RYKJ%1R6FTHVLK:'VGB#B,.UPM!U/>K<3 MY34A&-G[14HMJ22TG"+DU)*\;VO?0]M_X.AOV6/@%\*_!OPA^/\`X&^&NA^' MOB_\8OC3X@A^)7C>REU)]3\70V?@>6>U34H;F^GTZ+R9[6SF4Z?96;$P%9"X M*[?V?_9&_P""0W_!.6]^!G[-'Q9NOV6?`5Q\1;KX5?![X@W'BJ:^\6M?R^,Y M_"?AWQ')K[0GQ']C-T=;8W_E?9_LWF?NS"8ODK\Y?^#L5'E_9I_96E5':*+X MX^)H9I-K>5%*_@&_*1R2$!$9_)E*!B-XBD*Y"/C^B[]C'6=(OOV0/V7;VSU* MQNK*7]GGX-M'=6]S%+;,L?P\\.0RD3(QB_=2JT4OS?NY5:-]KHRCKS/,\QCP M-PK;,L="=3&YY1J\N*JQ=2C2K451I32E[U*FFXTX/W8JZBDCFRK*('%- M*MEV"DJ6`R7$TXU,/2;AB)PYZE:'-&ZG.=I5)K63;/YOO^#LF`P?L]?LD MAB&/_"X_'`W#/('@6/));)W,2Q(R0,@*``08_P#@M1^V]X]_9U_X)N_L<_L^ M?"/6;_0/'?[3'PD\$V&OZYH]S/:ZOIOPU\-^`?"B:QINF7%FZ7=O?>+]8UC3 M=$,D*R/+HMKXDL=@%X9&M_\`!VA(DG[/?[))1@V/C)XY)X(QGP+'C@@=<'\J M^3?^"_WP>\91_LM_\$QOVH?#-B][HGPY^%/A#P#XDNQ;_:[/0=4UCPGX,\5> M#;S4X&$L4=IJ=YHNM6+7_L`GT'#M'#XO`?2I MPJ6<:N(C3JUO5H9QXAU,$^2:RG(85JE"7).AAZ MD\/'$U(1IZZ4I2FG[`?\$[O^""_[('P%^!_A.\_:#^#G@?XZ?'?Q M1HEEJGQ!U+XFZ'9>,O#GA[4]2MH+BX\*^$_#6KK=^'K.TT(;-.EUW['=ZUK% MW%?WC:LNGWMM86='XX?\&[?[)OC7]H+X/_'/X&:IX@_9B@\'>.+'Q)\0?!OP MINKC3-*\0Z?I1_M'3SX#D>62;X9ZZ=8LM.@NKG0,Z8='ENUTW2M,U:WL-4A_ M6C]C?]K3X1_MC?`#P-\=?A3K^FWND>)](M+C6]#@U""[U?P7XDB@2/7?"?B. MUC;[3I^K:+J2W%HT5U!;_:K5(-2M8S8W=M(UGX\?MG?LR?LT>(?AIX4^.'QF M\&?#CQ!\6_$B>&?`VG:_J207.J7SQ._VV[V;X]$T!)?(M9?$.LFQT"VO[NPL M;K4H9[Z!)/@JF=\41S7%QEC

-MB*-3!*52HH8>,I)Q^JVDE3C!:/V?+!7: M:NV?H.%X>X0EDV!G/"9:L(EAJM/'N=.E.IB>6$N:6,4U.5253XHNHW)NTHW1 M_+U_P=/)XTT^_P#V);/Q!#XCOOV<[35O%TGBRVT:YE$MYXRBGT%6AFN;TS6: MZ[)X,.K+X=NM19]U_LZ_"S_@WW_;6^%OA[X>?"7X>_LP2W M=UI4$$7A*\AL/`7[0NF7DL<,4@O=4O;K2OB7?ZRL[6HGUBVUO6;;4;F)XFU# M5/)P?U[_`&B/$?[&_CVY\-_LR?M,:U\'/$%W\;M+OM1\(_"KXF7NARW'C>WT M$O% M_P`0/V9/'WB_]G#Q9H>D:QXDTK1]9\1S>-OA?#<:38W.JI;3ZAXHN9_%WAVQ MN3;[3KB^)]2705D>\BTB_BA.G3^WE>;9=B*J4N9K9/ENEX&<9'C:&<9QG678').)<)B:&%AC_L+_`+`?P&_X)_\`POU?X8_`2TUC M^QO$GB_5?&NMZSXKOK;5_%&JZAJ$LD=C97VJV5EI<5U8>'=*^SZ'HD36B20V M,,DMRUS?7VHW%U^8'[#NGV>K?\%;?V_M.OK:&ZM-0T'X@VEU;W$:S6\]E=?$ MCP.+JUFAD#)+%<*T:RHX972,QGY)&%>7?\&T?[8'QU_:!^"WQY^#WQG\3ZKX M\M/VS\9,_A:YURX9K[7+7PO<>"Q-IMWJ-Q? M:A'8>(+>R69-)LM/M;'US]@PA?\`@KU^WB6.`-)\=`Y]3\2/`0'UY('&:PE@ M<9E^)XMPN/KO$8NA@\-.5?FYWSRJPE"I"=W:7LW"5XM6;[GYSQKBL%FF=?1\ MJ8##>PP&)XYS*FL''F<)..18ZG5H3@VW.$X.NI4VG&I3C=IJ":\EUA-1_P"" M0?["&];]CS]H>?[-/%;6]U<6GA*Y%SYK11A&#/JO@>Z1KBSC0S7&H>#] M6OH[:*\U725C@W_V??#>O_\`!4[]M#6/VEOB#9W47[,?P%U:WTSX6>$]6MIQ M9^(-3@N8+^QMI+61Y+6:62\L;/Q;XP1@1ONO#VB*L]F@:']N/VL_V7O!7[6? MP7\3?"+QA&UDFIK'J/AOQ+;6J7>H>$_$]D)#I/B'3X'FMQ-+9O*Z3VHN+<7U MC/>6+3VXN3.G7?`'X%^"OV=_A-X.^$G@;3S9:%X.TM+-9953[9J]](3<:IK> MHNAV27^KZE+=ZCKGM5\T>4M4_P""M;?\9S_\$_)=%(Y^\/\`A9WACGCIG!J] M\5BB_P#!>SX#L7`5?AY/U(&0WPB^+B\9Y)RN2%!(&6("HQ'U!^WC^QE\9?VB M_P!J']E+XK_#P>%O^$1^#NLZ?J'BYM#?$VD:PDP5HET_4M)N[>Y=C*2B&.%_-61AB*5%D!!7CT*.18HU,K M>6%!.'.U43D*O%M.O[[68K`W,D&J75A<36/A_2%:VU6ZO[B. M\5!:VS%OD\NPF)QV/P\,+&3MC*5652*;C3I0G"4JCDDURJ*:;\[ON?U!X@<3 M9/PEP;G&8Y[B:$(4\FKX2GA7**Q>8XC$X"K0I8+!4N:,J]3$59QI>SA&3DWR MV;/&/^"`.NZI=_`+XT:#+Y@T71_BQ8W^ER2[VB2YU?PAHXU6TCSP`L>EV5S+ M&I&V>^E=@6E!/]`BAG)#$$#'8]0/J>.>GN>W%?G-_P`$N_V7M5_9>_95\/>& M/%=F;7QUXVU6]^(/C?3V.Y],UC7++3K.RT:5Q@//I.@:9I%C?[%2)=2BOA$F MPAG_`$3=^7W+_(_65[J26MN_O/YMW855F(#''4`[O\`=V@].I/? M_$\5:I,#T'/!X'(]*EJ^CVTNN]G?\TB9*Z5G9IQ::W5FF_O5U\[GX-?![_@D MKXP^%_\`P5B^*'_!1ZX^,WAO6?#'C^^\>7%O\,K?PCJEMK6G-XN\.:;X?B6? MQ))K$MC<+97&GR3NT6E*)TD1%,;!C7[KE_W6["@A5Y_ARPYP3C`ZX)([%L#- M7#'&>J(>_*J>0<@\CL0#]12E5(P54CT(&/RQ77CL;BLQG2GBZKJ2H86&$HNV ML:5.5Z:U_ECH>;EN3X+*HUZ>#A*%/%8ZOC\0I2YI3K5[N3YK+[3NG;HEYGX, M_M3?\$D?&G[1/_!3OX%?M_:;\9/#7AG0/@W_`,*D6_\`AO?>%-4U#6=;7X;> M(]:\03M;:[!JUM::>=5AUA(;=)=-NC;R1?,9%8,/WB.1&H.`O/UYIV!C&!CT[?E3Q6.Q.,C@Z=>?-3P%'ZMA8?\^Z M"?/R?^!N4NNY6`RG!Y;5QU;"P<*F8XCZUBY-W]I7Y>3GVT;BDK:[+T/PN^(W M_!*'QGXP_P""N_P^_P""D\/Q?\-67A?P;'HD4_PMG\+ZD^N7O]E_#C6_`C&/ MQ*FK"QA+S:O#J)W:3(B11O#O+D-7W)^W7^P-\!OV_O@Y=?"7XW:1,3:W$FI> M!_'.BI:VOC#X?>(S:M:KK7A_4YK:Y$<5Q$$@U?29XFTK6+6.."]A5X;.ZL_N MORT_N)V_A';..W;)QZ9/J:4JIX*@CT(%;U,WS&I6P.)6)G2Q&74*6&PE6D^6 M5.A0BHP@]'=_LQ?\%0=9\*?!&:><6^B#XE_'?X8W.G6D M]RV3!X2\$3Z_X9%^]N(TO+NQU/2GOW5EF=8FPOZ1?\$VO^"$WPH_8R^(;?M% M?&+XB:G^TG^TUF[N=,\'M,UB^UW6=0\5SV\EU8R M>+=?U:XOH[6YN(]-L],EEFN9_P!_MB?W5X)(^4<$\D].I/)/>EVK_='/7@5Z M6-XMSS,,/4P^(KX>G"O9XCZMA,/AY8BT5"U6I3IQFXM*\HIVAA)-W3P^'G)TH-/5-IM:+S/P;_`."@'_!)+Q=^ MV/\`MS_LO_M;Z#\9O#G@C1OV?)OAFVI^"M3\(ZEK6I>(E\"?$^3Q]<_8M5M- M9TZTL&O;24V$0FM;@Q39E9&0%3^[%OF6(,PVL,`CMN*+N`)`..>"0,\5;*(> MJJ?JH]_;W/YFE`"]`!]`!V`[>P`^@`[5Y&+S'%X["X/"8F494LOH_5L(HJWL MJ'-SJFM%>TVW?\CW,#E.#R_%9AC,-&4:V9XB.*Q;;NJF(45"4VNTH146O+[O MYWO^"D7_``0?\._M8_&4?M3_`+./QFU#]FO]I&>73KO6]^'+S3/$GA+Q?#:Q6MO/KNBW5Y:W$5A;3S:,U\;R\O?E#0_P#@A7_P M4%^.UQI7A?\`;U_X*:_$#XB_!73;N%]2^&W@CQI\2O$[^*K:UN`PCU"]\?)I M>AZ?J31*$&J:GX8\7:C9R37.V:Z/[Z7^M#:I&"`1Z8&/RZ4A5<'Y5QUQ@8R. MG'M7JT.*\\P^&HX2&)ISHT(UO3]7\$^&[_`.(.D>*?#%EJ M6N:KK6KOKDFD:+I%MH5U<+&DT\X%](Y7S,_SX?L4?L)_!?\`X*$?\%*_^"GO MP3^,W]KV-I9S_&OQ1X,\7>'KB*#Q!X,\7Q?M!Z-IMEKUD+A)K/48DL]1O=/O MM(OXY;'4M+N[BUD6.YCT^^L?]`:XA\Y,(B')^=3M`;H0Q)1MV-@3!_A8]PN/ MS$_9+_X)7?!#]D']J7XX?M6_#_Q9\2-8\=?'V'Q7!XNT?Q3JNB7?A?3X_%WC M>Q\>ZA_8EEI^AV%[`]OK%C#!8R76H7;+8S7<A@N,,32AGF)S',*SS M;,L+A:&%Q48J,O:8:M!QC>/14(N$G)2BUHU9V/&S'@;"2K\/X/+L%'^R<#C\ M5B,?AYUI(HN*;YI.3M)I+E:DK733M?\`!K5O^#?3_@I=::>_PA\)_P#! M3S7)OV!K[]RTL=U"NNV]M>/\` M,T4"WDJ6O[9?\$R?^"1?P#_X)N:)JFH^&;Z]^)7QK\8:=%8>+OC!XEL+*TU% MM,@E2=_#O@W2X$F7PQX=DNH[:XU&U%_J.IZU-9V$FMZC=P:=I5KI_P"O"JO. M%'7DX&21CD_D/R%*%4=%4<`<`#A1A1TZ`<#T'`KSL?Q7GF987ZKB,33C1E%. M4:&&HX7VDN5+FK>PA3]JY+5\[=WJ[GN9?P5P_EN)6,PF'KNJG>F\3BJV*5)7 MORT57SA:VEK'Q=^VQ^PE\!OV]O@O?\`P9^.^C75WIBS_P!K>%?%.AM9 MV?B_P%XGBM;JUM_$?A34KVSU""VO3;W5Q:WEG?VM]I>J6-Q^`?V5/^"G>K>$/@Q?2S^3H?_"P?CK\*[FRMY6!F:#P MIX&N/$?A_P"WC+B74;#4=*N+M%BA9XE#.?[(L#D8&#U&.OUHVKQ\J\=.!Q]/ M2LLKXBS;)\,\'A*].>&[G3C6A+V<^THVU2O>RMKG'"&2YY M7^LXRC5IXEPY)8G!XBM@\1**Y>6,ZE&:(;6=/"GA75;J$V]WXAT^PUR^UO7?$ M'BN1)ITB\4>(-4DFLY'AN-.TK3[RW@O$^O/^"H/_``2U^$'_``4L^''A_0O% MFKWG@/XI>`WU"Y^'/Q3TFQMM0O-(75C;?VAH'B#2YFB.N>$]4-K%)=V4=Y97 M5G>)%>65[%'+J5GJ7ZL[$'1%Y.3\HY/KTZ^]!1#C**<=,J#CZ<<5E5S[.*V9 M4\VJ8V=3&T)0]A5<84U1IQ7+[.-.DHPD_LU;X[2[\%^%_&GQPU/3+K16\E;BUC^%NIZWH?@;3%F@B!DA M;6=0M4,TSF&[;Y9_L+]G3_@WTTK]EO\`;Z^#W[4WP@^,UC'\(/A+%HXM/AMX MC\/ZIJ?C;6K^/X83>"_$NN:IXOCU2WT=+_Q-XKO;_P`6F"Q\/6NGVD&H-86M MK&ELDDG].X1`I)^I->C6XRX@KT:F M&GBJ*PU6C7I5*%+"4*$*SKRYG*O*E",ZC6R\.86>&J0I8JM5 MPM>E6H5\5BZV(K453NU3H\\G""N]&H72=M;(_/S_`(**_L$_#G_@HA^SKJ?P M*\?ZS?>$[JSUNQ\8>`O'&EVUO?WW@[QEI=IJ%C9ZFVFW+)#JFG7-CJNIZ7JV MFM-9R7>FW]PMK>V%XEM>P_@C^SC_`,$`/VY?A9\1OA;9>+O^"AEWR\1+I`\!W^O:=X.\/)J$MH(A,MSKJ6K2W M,@M;K?F7^O':O/RKSUX'.>N>*-B9!VKD`@':,@'&0#CH=JY^@]!7#E_$6<9= M@*N68?%IX"K*I4^JUJ%"O"E5K*/MI49U82J4XU&MHR5K)IZV/2S#A+)*O^"FG MPU^#/@3PM\6/#_PIN/AEXUU[Q7>:EKWA?4?$L&K1:MX>CT5;.W@T_5=+DMI( M9`;HR2RS)(@\L+&,S+]YWG[,/PY\;?LOZ%^S)\:=$TCXE^!4^%OA7X;^*=-U M&S>*PUS^P="T[2?[4LHVE-YI5W'=V<>IZ-=6EQ'J>EWT5KH!^H'^>PHVJ1@JN,8Q@8QZ8]*XJF9YC5P>!P4ZZ=#+<14Q6`IQ4J:PV(K3< MZM6,X-3E*3E)I2=E)]K)=T,BRZ..QN/="-2MF>'HX3'\Z4HUJ&'IPIT86V_W#]E#_@W-@MO MB_IWQZ_X*%?M#ZQ^UCXXTJZL]3A\(RWGB;5_#&JZE9,)+?\`X3GQ7XYOKWQ1 MXXTR*0R3+HK6&@Z?/'(EIJ2ZC9?;8=2_J;$<:X"HB@8P`JC&!@8P.PX'H..E M."J.`J@<\``=3D_F>3[U[E3C3B&IA981XNE"G.G&G*K#"8>.+G"*LX5,4H*M M*,EO[U]7KU/"I\`<-T\5#%_5:TYTZOMJ5&IBL1+!TYZ>]'"<_L>967*^5)=C M\3/^"E7_``14^!?_``4)U;0?B.?&_C+X._'+PAX;TSPEX7\<>'KD:KX<3PYH MMQ=W>C^']4\&7<]M!!IFG7%]J$UD_A:_\/7D,U[=O/+="=U/Y1WW_!!;_@J7 MK>CR_"#Q7_P56\3:O\!KR/\`LZ^T*]\;_'768Y]#41P)8S_#[4?$;:!=6/EN M5719O$KZ()O*DDM'$0!_L.V)G.UG4=O2EVK_='Y"L,%Q7GV`P] M/"T,72E0I1G[*-?"86N\.YRC)>PE4I2E!1L^5M\RNG=.]^C,.".'\RQ4L;B, M-7AB*EU6EA\9B:$,0FTVJT*NM4U9_$_CSQSKRVD6M>-O$TT,-LU[[5QMVKM`P! M@8`QC&,8QCC'I2&*(D$QQDCH2BDCIT...@_(>E>5+,L=.>.J3KRJUH)A\^<,>,9!P.0>O!X] M_P#)M4F!Z#\JX;>ZX]X\M_NUMUVV/J^6+23BFE;1W5K:IJSZ-+KL?B;^V)_P M3+^+G[0O[3L?[1_PM_:*3X+Z[8^$=&\/:1=Z5I?B&'Q5I,]C;:S8W][IGB70 M/$NAWED-1L-8GL)C;")Y+"XO;21_+N&KR)/^"8G_``4#!"M_P4Y^*N\?)O/B MOXQ[SZ;L?$OEF^\26RS'Y_,^M&Q.FU<'J-HY_2O= MH\19E2I4Z+>&J0H0A3H^TPU*I*,(I+EU<)75O9U*4LTQN*C^[:O%^S4XNSC)-%:T& M$D`!P)"`<``@*O*G EX-99.1 3 ex-99_1.htm PRESS RELEASE

 

  

 

FOR IMMEDIATE RELEASE   SYMBOL: TXMD
July 10, 2012  TRADED: OTCQB

 

THERAPEUTICSMD, INC. ANNOUNCES PLANS IN HORMONE THERAPY THAT CONCUR WITH THE RECENT JOINT STATEMENT FROM NAMS, ASRM AND THE ENDOCRINE SOCIETY

 

FOR IMMEDIATE RELEASE – July 10, 2012 – Boca Raton, FL – TherapeuticsMD™, Inc. [OTCQB: TXMD], parent company of vitaMedMD®, LLC ("vitaMedMD"), a specialty pharmaceutical company ("TherapeuticsMD" or the "Company"), announced today its plans to file up to three Investigational New Drug applications (“INDs”) with the U.S. Food and Drug Administration (“FDA”) this year and if accepted, will initiate Phase III clinical trials in the field of hormone therapy for menopausal women. During the same time period, the Company expects to file additional patents for these products.

 

Robert Finizio, the Company's Chief Executive Officer, stated, "We are excited at the clarity provided by the recent joint statement of agreement regarding the benefits of hormone therapy for symptomatic menopausal women issued by the leading medical societies devoted to the care of menopausal women. We believe the joint statement reaffirms the overall direction for the Company’s hormonal platform of providing women with treatment for their menopause symptoms." (The joint statement of agreement can be found on the NAMS website at www.menopause.org.)

 

About TherapeuticsMD

TherapeuticsMD is a specialty pharmaceutical company focused on creating safe and effective therapies exclusively for women. The Company’s branded OTC and pharmaceutical products are designed to improve the health and well-being of women from pregnancy through menopause.  vitaMedMD provides dietary supplements and healthcare products focused on improving women’s health, wellness, and quality of life. Questions may be directed to Daniel A. Cartwright, the Company's Chief Financial Officer, at (561) 961-1911. More information on TherapeuticsMD is available on its website at www.therapeuticsmd.com. More information on vitaMedMD and its products are available at www.vitamedmdrx.com and www.vitamedmd.com.

 

This press release shall not constitute an offer to sell or a solicitation of an offer to buy securities of TherapeuticsMD, Inc. Certain statements in this release and other written or oral statements made by or on behalf of the Company are “forward-looking statements” within the meaning of the federal securities laws. Statements regarding future events and developments and our future performance, as well as management’s expectations, beliefs, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws and include our plans to file up to three INDs, our initiation of Phase III clinical trials if the INDs are accepted by the FDA, our expectations to file additional patents for these products, and our beliefs regarding the joint statement’s reaffirmation of the overall direction of our Company’s hormonal platform. The forward-looking statements are subject to a number of risks and uncertainties including FDA and market acceptance of the Company’s services and projects and the Company’s continued access to capital and other risks and uncertainties identified in the Company’s Form 10-K and other filings with the Securities and Exchange Commission. The actual results the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. These statements are based on our current expectations and speak only as of the date of such statements. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of future events, new information or otherwise.

 

# # #